Ankylosing SpondylitisPhase 4NCT06833112
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
A Phase 4 study testing Secukinumab and Adalimumab in people with Ankylosing Spondylitis, run by The Affiliated Hospital Of Guizhou Medical University at 1 site in China.
Trial summary
The aim of the study is to investigate the efficacy and safety of adalimumab in combination with secukinumab for the treatment of ankylosing spondylitis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ankylosing Spondylitis
- What is being tested?
- Secukinumab and Adalimumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteChina
- Study dates
- Feb 2025to Feb 2028
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female at least 18 years old;
- diagnosed with AS according to the 1984 New York Modified Criteria;
- Poor response after at least 2 NSAIDs (cumulative treatment ≥ 4 weeks), or contraindication or intolerance to NSAIDs therapy;
- BASDAI score of ≥ 4 and total back pain VAS score of ≥ 4 at baseline;
- Subjects who need to take NSAIDs (including COX-1 or COX-2 inhibitors) as established treatment for AS, and the NSAIDs should be on a stable dose for at least 2 weeks (inclusive) before screening and the dose is expected to be stable during the study;
- Voluntary treatment with adalimumab and secukinumab;
Show all 9Show fewer
- Appropriate contraceptive measures for women of childbearing age;
- without other rheumatic diseases.
- Able to understand study requirements, provide written informed consent, and comply with trial protocol procedures (including required visits)
Who cannot join
- With unstable vital signs, coma, mental and cognitive impairment;
- Patients with severe systemic diseases and other serious chronic diseases;
- Pregnant or lactating patients;
- History of malignant tumor in the past 5 years;
- Positive test for the following infection markers: human immunodeficiency virus (HIV), hepatitis B, hepatitis C, syphilis antibody;
- Patients with active or recurrent history of infection; With active tuberculosis or have a history of active tuberculosis in the past;
Show all 10Show fewer
- Moderate to severe heart failure (New York Heart Association grade 3-4);
- Allergic to any of the components of adalimumab (HS016) or secukinumab;
- Subjects who are participating in clinical research of other drugs;
- In addition to the above, the investigator judged that there are other reasons that are not suitable for participating in this clinical study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, 550002
Jiashun Zeng, Doctor, 13984846802, zengjiashun@sina.com
About this study
Official title: Efficacy and Safety of Interleukin-17 Inhibitor in Combination With Tumor Necrosis Factor α Inhibitor in the Treatment of Ankylosing Spondylitis
The aim of the study is to investigate the efficacy and safety of adalimumab in combination with secukinumab for the treatment of ankylosing spondylitis.
- Conditions
- Ankylosing Spondylitis
- Being tested
- Secukinumab, Adalimumab
- Keywords
- ankylosing spondylitis, Secukinumab, adalimumab
- Medical subject headings
- Spondylitis, Ankylosing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SecukinumabDrug
The subjects were treated with secukinumab for 104 weeks. Secukinumab:150mg,q8w,subcutaneous injection.
AdalimumabDrug
The subjects were treated with adalimumab for 104 weeks. adalimumab: 40mg,q4w,subcutaneous injection.
| Study group | Role | What they receive |
|---|---|---|
| treatment group | Experimental | The subjects were treated with adalimumab (HS016) in combination with secukinumab Receives: Drug: Secukinumab; Drug: Adalimumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of SpondyloArthritis International Society 40 (ASAS 40)
Proportion of subjects achieving ASAS 40 at Week 52. ASAS 40 is a response criterion used to evaluate the effectiveness of treatments in patients with ankylosing spondylitis. It measures the percentage of patients who achieve at least a 40% improvement in disease activity.
Key Components of ASAS40:
- Patient Global Assessment:Patient's overall assessment of disease activity
- Pain: Assessment of spinal pain.
- Function: Measured by the Bath Ankylosing Spondylitis Functional Index (BASFI).
- Inflammation: Based on morning stiffness severity and duration.
Calculation:
A patient is considered an ASAS40 responder if they achieve at least a 40% improvement or an absolute improvement of ≥2 units (on a 0-10 scale) in at least 3 out of 4 domains, with no worsening in the remaining domain.
Measured: week 52
ASAS40
- Proportion of subjects achieving ASAS 40 at Week 104. ASAS 40 is a response criterion used to evaluate the effectiveness of treatments in patients with ankylosing spondylitis. It measures the percentage of patients who achieve at least a 40% improvement in disease activity.
Key Components of ASAS40:
- Patient Global Assessment:Patient's overall assessment of disease activity
- Pain: Assessment of spinal pain.
- Function: Measured by the Bath Ankylosing Spondylitis Functional Index (BASFI).
- Inflammation: Based on morning stiffness severity and duration.
Calculation:
A patient is considered an ASAS40 responder if they achieve at least a 40% improvement or an absolute improvement of ≥2 units (on a 0-10 scale) in at least 3 out of 4 domains, with no worsening in the remaining domain.
Measured: week 104
Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)
The mSASSS is a method used to assess spinal damage and function in patients with ankylosing spondylitis.
The assessment Items includes:
- Vertebral Scoring: It evaluates the morphology of each vertebra from T1 to L5. Each vertebra is scored from 0 to 3 based on the presence and degree of squaring, erosions, and syndesmophytes. For example, 0 means normal vertebra, and 3 indicates severe structural changes.
- Intervertebral Disc Scoring: The intervertebral discs between the vertebrae are also assessed. The score ranges from 0 to 2, depending on the presence and extent of disc space narrowing and bridging syndesmophytes.
Total Score Calculation: The scores of all vertebrae and intervertebral discs are summed up to obtain the mSASSS total score. The higher the score, the more severe the spinal damage.
Measured: week 104
Spondyloarthritis Research Consortium of Canada (SPARCC)
The SPARCC assessment method is a valuable tool in the field of spondyloarthritis research and diagnosis.
The assessment Items include:
- Sacroiliac Joint Assessment: It evaluates the sacroiliac joints using magnetic resonance imaging (MRI). The assessment includes aspects such as bone marrow edema, erosion, and fatty infiltration in the sacroiliac joints. Each feature is scored based on its severity and extent.
- Spinal Assessment: For the spine, SPARCC also uses MRI to assess inflammation. It focuses on detecting signs like vertebral corner inflammation (enthesitis) and discitis. Similar to the sacroiliac joint assessment, specific features are scored according to their characteristics.
Scoring System: The total SPARCC score is obtained by summing up the scores of different items. Higher scores indicate more severe inflammation and greater disease activity.
Measured: week 104
Secondary outcomes (13)
Assessment of SpondyloArthritis International Society 20 (ASAS20)
Proportion of subjects achieving ASAS 40 at week 12, week 24, week 52. ASAS 20 is a response criterion used to evaluate the effectiveness of treatments in patients with ankylosing spondylitis. It measures the percentage of patients who achieve at least a 20% improvement in disease activity.
Key Components of ASAS20: -Patient Global Assessment:Patient's overall assessment of disease activity -Pain: Assessment of spinal pain. -Function: Measured by the Bath Ankylosing Spondylitis Functional Index (BASFI). -Inflammation: Based on morning stiffness severity and duration.
Calculation: A patient is considered an ASAS20 responder if they achieve at least a 20% improvement or an absolute improvement of ≥1 units (on a 0-10 scale) in at least 3 out of 4 domains, with no worsening in the remaining domain.
Measured: week 12, week 24, week 52
Assessment of SpondyloArthritis International Society 5/6 (ASAS5/6)
Proportion of subjects achieving ASAS5/6 at week 12, week 24, week 52. A patient is considered an ASAS5/6 responder if they achieve at least a 20% improvement in at least five of the six items mentioned below:
- Patient's Global Score: The patient's overall pain level is assessed by the Visual Analogue Score (VAS).
- Patient's nocturnal back pain and overall back pain VAS score: special attention is paid to the condition of nocturnal back pain.
- BASFI (Bath Ankylosing Spondylitis Functional Index): Evaluates the patient's ability to perform daily activities, such as wearing socks, bending over to pick up objects, etc.
- Inflammatory response: by the mean score of inflammatory indicators and morning stiffness time in BASDAI (Bath Ankylosing Spondylitis Disease Activity Index).
- CRP (C-reactive protein): assesses the level of inflammatory markers.
- Spinal range of motion: By measuring the range of motion of the spine, such as scoliosis.
Measured: week 12, week 24, week 52
Assessment in Ankylosing Spondylitis international Society Partial Release (ASAS PR)
Proportion of subjects achieving ASAS PR at week 12, week 24, week 52 (The absolute score for each of the 4 indicators identified in ASAS 40 ≤ 2 units)
Measured: week 12, week 24, week 52
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50
Proportion of subjects achieving BASDAI 50 at week 12, week 24, week 52. BASDAI50 is defined as a patient who has at least a 50% improvement from baseline in BASDAI score over the course of treatment.
Assessment Domains (each scale from 0 to 10, the higher the score, the more severe the symptom):
- Fatigue: Patients are asked to rate their level of fatigue in the past week.
- Spinal Pain: score the average spinal pain they have experienced in the past week.
- Joint Pain/Swelling: Patients rate the degree of pain and swelling in their joints in the past week.
- Localized Tenderness: The pain at the sites where tendons and ligaments attach to bones is evaluated.
- Morning Stiffness: This is divided into two parts: duration and severity.
Scoring Calculation:
The scores of the five aspects above are added together, resulting in a total score ranging from 0 to 50. This total score is then divided by 5 to obtain the final BASDAI score, which ranges from 0 to 10.
Measured: week 12, week 24, week 52
BASDAI
Change from baseline in BASDAI score at week 12, week 24, week 52.
Assessment Domains (each scale from 0 to 10, the higher the score, the more severe the symptom):
- Fatigue: Patients are asked to rate their level of fatigue in the past week.
- Spinal Pain: score the average spinal pain they have experienced in the past week.
- Joint Pain/Swelling: Patients rate the degree of pain and swelling in their joints in the past week.
- Localized Tenderness: The pain at the sites where tendons and ligaments attach to bones is evaluated.
- Morning Stiffness: This is divided into two parts: duration and severity.
Scoring Calculation:
The scores of the five aspects above are added together, resulting in a total score ranging from 0 to 50. This total score is then divided by 5 to obtain the final BASDAI score, which ranges from
Measured: week 12, week 24, week 52
Bath Ankylosing Spondylitis Functional Index (BASFI)
Change from baseline in BASFI score. The BASFI assesses a patient's ability to perform 10 daily activities. These include things like bending to pick up an object from the floor, getting in and out of a car, and turning around in bed.
Scoring Process
- Each activity is scored on a scale from 0 to 10. A score of 0 means the patient can perform the activity without any difficulty, while a score of 10 indicates that the patient is completely unable to do the activity.
- After scoring each activity, the scores are added together. The sum ranges from 0 to 100.
- This sum is then divided by 10 to get the final BASFI score, which ranges from 0 to 10.
The lower the score, the lower the disease activity.
Measured: week 12, week 24, week 52
Visual Analogue Scale (VAS)
Change from baseline in VAS score. The VAS (Visual Analogue Scale) scoring method is a commonly used tool for quantitative assessment in medicine that allows patients to directly mark their perceived degree of a certain symptom or condition on a straight line. It transforms subjective feelings into objective numerical values for quantification and comparison.
Scoring Process: a 10-cm straight line is used, with the left end marked as 0 representing no symptom or the best condition, and the right end marked as 10 representing the most severe symptom or the worst condition.
Measured: week 12, week 24, week 52
Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
The Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) is used to evaluate enthesitis in patients with ankylosing spondylitis.
Evaluation Sites:The MASES assesses 13 enthesis sites, namely the left and right first costochondral joints, the left and right seventh costochondral joints, the left and right posterior superior iliac spines, the left and right anterior superior iliac spines, the left and right iliac crests, the proximal insertions of the left and right Achilles tendons, and the fifth lumbar spinous process.
Scoring Criteria:Absence of pain at the enthesis site is scored as 0, and presence of pain is scored as 1. The total score is the sum of the scores of all sites, ranging from 0 to 13.
Measured: week 12, week 24, week 52
tender joint count (TJC), swollen joint count(SJC)
Change from baseline in 44 TJC and 44 TJC
Measured: week 12, week 24, week 52
Ankylosing Spondylitis Disease Activity Score based on C-reactive Protein (ASDAS-CRP)
Change from baseline in ASDAS-CRP. Components of Assessment: 1)Patient Global Assessment : Patients rate their overall disease activity in the past week on a 0 - 100 mm Visual Analogue Scale, with 0 indicating no disease activity and 100 representing the most severe activity.2)Spinal Pain: The patient assesses the pain in the spine in the past week on a 0 - 100 mm VAS, where 0 means no pain and 100 is the most intense pain.3) Inflammatory Back Pain: It is scored based on a binary scale, 0 for no pain.4)C-reactive Protein level.
Calculation of the Score:
The ASDAS-CRP score is calculated through a specific formula: ASDAS-CRP = 0.12 × PGA + 0.28 × spinal pain + 0.16 × IBP + 0.10 × ln(CRP + 1). The result of the calculation is the ASDAS-CRP score, which is used to classify the disease activity level. Generally, a score of <1.3 indicates inactive disease, 1.3 - 2.1 indicates low disease activity, 2.1 - 3.5 indicates moderate disease activity, and >3.5 indicates high disease activity.
Measured: week 12, week 24, week 52
Ankylosing Spondylitis Disease Activity Score based on Erythrocyte Sedimentation Rate (ASDAS-ESR)
Change from baseline in ASDAS-ESR. Assessment Elements: 1)Patient Global Assessment: Similar to ASDAS-CRP, patients rate their overall disease activity in the past week on a 0 - 100 mm Visual Analogue Scale (VAS), with 0 meaning no disease activity and 100 being the highest level of activity.2)Spinal Pain: Patients assess their spinal pain in the past week on a 0 - 100 mm VAS, where 0 represents no pain and 100 is the worst pain.3)Inflammatory Back Pain (IBP): It is scored as 0 for no IBP and 1 for having IBP.4)Erythrocyte Sedimentation Rate (ESR): The ESR value in mm/h is used as a key indicator.
Score Calculation:The formula for calculating ASDAS-ESR is: ASDAS-ESR = 0.12 × PGA + 0.28 × spinal pain + 0.16 × IBP + 0.08 × ln(ESR + 1). The calculated score is used to determine the disease activity level. Typically, a score of <1.3 suggests inactive disease, 1.3 - 2.1 indicates low disease activity, 2.1 - 3.5 represents moderate disease activity, and >3.5 means high disease activity.
Measured: week 12, week 24, week 52
Ankylosing Spondylitis Quality of Life (ASQoL)
Change from baseline in ASQoL. The ASQoL questionnaire consists of 19 questions covering various aspects such as pain, physical function, mental state, and social life. For example, questions about the impact of the disease on daily activities like dressing, walking, and climbing stairs; how the disease affects mood, sleep, and relationships with others.
Scoring Method: Each question is scored on a 5-point scale, usually from 0 to 4, with 0 indicating no impact on quality of life and 4 indicating a very severe impact. The scores of all questions are summed up. The total score ranges from 0 to 76. A higher score indicates a poorer quality of life.
Measured: week 12, week 24, week 52
Adverse event (AE)
Incidence of adverse events
Measured: week 12, week 24, week 52,week 104
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2025
- Study startFeb 2025 (estimated)
- Primary completionAug 2027 (estimated)
- Study completionFeb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ankylosing SpondylitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Affiliated Hospital Of Guizhou Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jiashun Zeng, Medical Doctor, Principal investigator, The Affiliated Hospital Of Guizhou Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06833112
- Sponsor's protocol ID
- 2024114K
- Status last verified
- Jan 2025
- First submitted
- 22 Jan 2025
- Last updated
- 18 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Interleukin-17 Inhibitor in Combination With Tumor Necrosis Factor α Inhibitor in the Treatment of Ankylosing Spondylitis
- ClinicalTrials.gov ID
- NCT06833112
- Acronym / sponsor ID
- 2024114K
- Conditions
- Ankylosing Spondylitis
- Keywords
- ankylosing spondylitis, Secukinumab, adalimumab
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- The Affiliated Hospital Of Guizhou Medical UniversityUniversity, hospital or other
- Study start
- Feb 2025 (estimated)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Feb 2028 (estimated)
- First posted
- 18 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to investigate the efficacy and safety of adalimumab in combination with secukinumab for the treatment of ankylosing spondylitis.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| treatment group | Experimental | Drug: Secukinumab, Drug: AdalimumabThe subjects were treated with adalimumab (HS016) in combination with secukinumab |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Male or female at least 18 years old;
- diagnosed with AS according to the 1984 New York Modified Criteria;
- Poor response after at least 2 NSAIDs (cumulative treatment ≥ 4 weeks), or contraindication or intolerance to NSAIDs therapy;
- BASDAI score of ≥ 4 and total back pain VAS score of ≥ 4 at baseline;
- Subjects who need to take NSAIDs (including COX-1 or COX-2 inhibitors) as established treatment for AS, and the NSAIDs should be on a stable dose for at least 2 weeks (inclusive) before screening and the dose is expected to be stable during the study;
Key exclusion criteria (10 listed)
- With unstable vital signs, coma, mental and cognitive impairment;
- Patients with severe systemic diseases and other serious chronic diseases;
- Pregnant or lactating patients;
- History of malignant tumor in the past 5 years;
- Positive test for the following infection markers: human immunodeficiency virus (HIV), hepatitis B, hepatitis C, syphilis antibody;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SecukinumabThe subjects were treated with secukinumab for 104 weeks. Secukinumab:150mg,q8w,subcutaneous injection. | Drug | treatment group |
| AdalimumabThe subjects were treated with adalimumab for 104 weeks. adalimumab: 40mg,q4w,subcutaneous injection. | Drug | treatment group |
Primary outcome
Assessment of SpondyloArthritis International Society 40 (ASAS 40)
Time frame: week 52
Proportion of subjects achieving ASAS 40 at Week 52. ASAS 40 is a response criterion used to evaluate the effectiveness of treatments in patients with ankylosing spondylitis. It measures the percentage of patients who achieve at least a 40% improvement in disease activity. Key Components of ASAS40: * Patient Global Assessment:Patient's overall assessment of disease activity * Pain: Assessment of spinal pain. * Function: Measured by the Bath Ankylosing Spondylitis Functional Index (BASFI). * Inflammation: Based on morning stiffness severity and duration. Calculation: A patient is considered an ASAS40 responder if they achieve at least a 40% improvement or an absolute improvement of ≥2 units (on a 0-10 scale) in at least 3 out of 4 domains, with no worsening in the remaining domain.
ASAS40
Time frame: week 104
1. Proportion of subjects achieving ASAS 40 at Week 104. ASAS 40 is a response criterion used to evaluate the effectiveness of treatments in patients with ankylosing spondylitis. It measures the percentage of patients who achieve at least a 40% improvement in disease activity. Key Components of ASAS40: * Patient Global Assessment:Patient's overall assessment of disease activity * Pain: Assessment of spinal pain. * Function: Measured by the Bath Ankylosing Spondylitis Functional Index (BASFI). * Inflammation: Based on morning stiffness severity and duration. Calculation: A patient is considered an ASAS40 responder if they achieve at least a 40% improvement or an absolute improvement of ≥2 units (on a 0-10 scale) in at least 3 out of 4 domains, with no worsening in the remaining domain.
Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)
Time frame: week 104
The mSASSS is a method used to assess spinal damage and function in patients with ankylosing spondylitis. The assessment Items includes: * Vertebral Scoring: It evaluates the morphology of each vertebra from T1 to L5. Each vertebra is scored from 0 to 3 based on the presence and degree of squaring, erosions, and syndesmophytes. For example, 0 means normal vertebra, and 3 indicates severe structural changes. * Intervertebral Disc Scoring: The intervertebral discs between the vertebrae are also assessed. The score ranges from 0 to 2, depending on the presence and extent of disc space narrowing and bridging syndesmophytes. Total Score Calculation: The scores of all vertebrae and intervertebral discs are summed up to obtain the mSASSS total score. The higher the score, the more severe the spinal damage.
Spondyloarthritis Research Consortium of Canada (SPARCC)
Time frame: week 104
The SPARCC assessment method is a valuable tool in the field of spondyloarthritis research and diagnosis. The assessment Items include: * Sacroiliac Joint Assessment: It evaluates the sacroiliac joints using magnetic resonance imaging (MRI). The assessment includes aspects such as bone marrow edema, erosion, and fatty infiltration in the sacroiliac joints. Each feature is scored based on its severity and extent. * Spinal Assessment: For the spine, SPARCC also uses MRI to assess inflammation. It focuses on detecting signs like vertebral corner inflammation (enthesitis) and discitis. Similar to the sacroiliac joint assessment, specific features are scored according to their characteristics. Scoring System: The total SPARCC score is obtained by summing up the scores of different items. Higher scores indicate more severe inflammation and greater disease activity.
13 secondary outcomes
Assessment of SpondyloArthritis International Society 20 (ASAS20)
Time frame: week 12, week 24, week 52
Assessment of SpondyloArthritis International Society 5/6 (ASAS5/6)
Time frame: week 12, week 24, week 52
Assessment in Ankylosing Spondylitis international Society Partial Release (ASAS PR)
Time frame: week 12, week 24, week 52
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50
Time frame: week 12, week 24, week 52
BASDAI
Time frame: week 12, week 24, week 52
Bath Ankylosing Spondylitis Functional Index (BASFI)
Time frame: week 12, week 24, week 52
Visual Analogue Scale (VAS)
Time frame: week 12, week 24, week 52
Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)
Time frame: week 12, week 24, week 52
tender joint count (TJC), swollen joint count(SJC)
Time frame: week 12, week 24, week 52
Ankylosing Spondylitis Disease Activity Score based on C-reactive Protein (ASDAS-CRP)
Time frame: week 12, week 24, week 52
Ankylosing Spondylitis Disease Activity Score based on Erythrocyte Sedimentation Rate (ASDAS-ESR)
Time frame: week 12, week 24, week 52
Ankylosing Spondylitis Quality of Life (ASQoL)
Time frame: week 12, week 24, week 52
Adverse event (AE)
Time frame: week 12, week 24, week 52,week 104
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Ankylosing Spondylitis
RecruitingPhase 1
A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
Psoriasis, Ankylosing Spondylitis
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingObservational study
Identification of Serum Level of Glutathione Peroxidase 4
Spondyloarthropathy
Not yet recruitingPhase 1
A Study of GKL-006Allo Injection in Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
Active, not recruitingObservational study
Neuropathic Spinal Pain in Ankylosing Spondylitis
Ankylosing Spondylitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jiashun Zeng, Medical Doctor principal investigator
The Affiliated Hospital Of Guizhou Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Secukinumab and Adalimumab in people with Ankylosing Spondylitis, run by The Affiliated Hospital Of Guizhou Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jiashun Zeng, Medical Doctor (13984846802, zengjiashun@sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of SpondyloArthritis International Society 40 (ASAS 40) (time frame: week 52). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2025.